Search results
Showing 391 to 405 of 1251 results for public health guidance
Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129]
Awaiting development Reference number: GID-TA11218 Expected publication date: TBC
Awaiting development Reference number: GID-TA11867 Expected publication date: TBC
Awaiting development Reference number: GID-TA11326 Expected publication date: TBC
Our science policy and research programme team produces high-quality, impactful research.
In development Reference number: GID-TA11959 Expected publication date: TBC
This quality standard covers the effective use of antimicrobial medicines (including antibiotics) to reduce the risk of antimicrobial resistance, which is when antimicrobial medicines lose their effectiveness. It covers all settings and all types of antimicrobials for treating bacterial, fungal, viral and parasitic infections. It describes high-quality care in priority areas for improvement.
View quality statements for QS121Show all sections
Sections for QS121
- Quality statements
- Quality statement 1: Advice on self-limiting conditions
- Quality statement 2: Back-up (delayed) prescribing
- Quality statement 3: Recording information
- Quality statement 4: Microbiological samples
- Quality statement 5: Data collection and feedback
- Quality statement 6 (developmental statement): electronic prescribing systems
- Update information
Awaiting development Reference number: GID-TA11487 Expected publication date: 27 May 2027
Awaiting development Reference number: GID-TA11885 Expected publication date: TBC
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]
Awaiting development Reference number: GID-TA11775 Expected publication date: TBC
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]
Awaiting development Reference number: GID-TA11526 Expected publication date: TBC
Awaiting development Reference number: GID-TA10967 Expected publication date: TBC
Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620]
Awaiting development Reference number: GID-TA11403 Expected publication date: 27 May 2027
Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433]
Awaiting development Reference number: GID-TA11489 Expected publication date: TBC
Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663]
Awaiting development Reference number: GID-TA11883 Expected publication date: 23 September 2027
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development Reference number: GID-TA11881 Expected publication date: TBC